Abstract
Objectives: In vitro trends of cefazolin and ceftriaxone susceptibilities from pediatric clinical isolates of methicillin-susceptible Staphylococcus aureus (MSSA) between 2011 and 2016 were analyzed for surveillance. Methods: Our laboratory continues to use agar disk diffusion for staphylococcal susceptibilities applying Clinical Laboratory Standard Institute's 2012 breakpoints. Results: A total of 3992 MSSA clinical isolates in the last 6 years were analyzed for their in vitro cefazolin and ceftriaxone susceptibilities. While all MSSA isolates exhibited cefazolin susceptibilities within the "susceptible" zone range, there have been a proportion of isolates with ceftriaxone susceptibilities falling in "intermediate" zones, ranging from 2.6% in 2011 to 8.3% in 2016. Conclusions: Cefazolin continues to be the recommended agent for MSSA treatment at our institution, reflected by the finding that only 2% (6/321) of patients who received ceftriaxone as definitive therapy for MSSA bacteremia during the study period. We have confirmed the cefoxitin-predicted MSSA susceptibility to cefazolin, but have found concerning drifts in ceftriaxone susceptibilities by continued in vitro monitoring over the last 6 years.
Original language | English (US) |
---|---|
Article number | 5 |
Journal | Annals of Clinical Microbiology and Antimicrobials |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Feb 20 2018 |
Externally published | Yes |
Keywords
- Cefazolin
- Ceftriaxone
- MIC
- MSSA
- Staphylococcus aureus
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases